Proton Therapy Struggles: SIAMH Faces Financial Hurdles and Auditor Concerns

Singapore Institute of Advanced Medicine Holdings Ltd. (SIAMH), listed on the Catalist of the Singapore Exchange, has reported several critical issues that may affect its share value. The company’s financial performance for the year ending 30 June 2024 was marked by mounting losses, auditor concerns, and challenges in adopting new medical technology, raising alarms for shareholders.

Key Financial Performance and Challenges

SIAMH reported a loss of \$37.4 million for the financial year, with net cash used in operating activities amounting to \$12.9 million. The company’s cash reserves dwindled to \$3.16 million, a substantial decrease from \$11.05 million the previous year. Revenue from the Medical Diagnostics and Treatment segment also saw a decline of 5% due to increased market competition.

Auditor Disclaimer and Financial Concerns

Crucially, the independent auditors issued a disclaimer of opinion on the consolidated financial statements, emphasizing concerns over the company’s going concern status, impairment of property, plant, and equipment (PPE), and receivables from subsidiaries. The audit committee did not find it prudent to impair PPE, despite auditors being unable to obtain adequate evidence.

Proton Therapy Adoption Slower Than Expected

The adoption of proton beam therapy, which was expected to revolutionize cancer treatment, has been slower than anticipated. Factors such as delays in insurance panel inclusion and lower patient referrals have hindered growth. The company’s projections for patient acquisition were not fully realized, and competition from other providers also posed a challenge.

Strategic Review Initiated

In response to these issues, SIAMH has established a strategic review committee to explore measures to enhance operational performance and financial stability. The committee is composed of current directors and aims to reassess internal strategies and address underperformance and cost overruns.

Outlook and Shareholder Concerns

Shareholders should be aware of the company’s ongoing challenges, including its dependence on advanced technology and the slow uptake of its services. The potential for increased patient flow and insurance coverage remains a focus, but the path to profitability is uncertain.

The company’s efforts to secure additional funding and strategic partnerships indicate a commitment to overcoming these hurdles. However, the impact on share value will largely depend on the successful implementation of these strategies and the resolution of auditor concerns.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult a financial advisor before making investment decisions.

View SAM Holdings Historical chart here